A Multi Center Extension Study of PRX-102 Administered by Intravenous Infusions Every 2 Weeks for 24 Months to Adult Fabry Patients [EXTENSION OF 700239938]

Trial Profile

A Multi Center Extension Study of PRX-102 Administered by Intravenous Infusions Every 2 Weeks for 24 Months to Adult Fabry Patients [EXTENSION OF 700239938]

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Pegunigalsidase alfa (Primary)
  • Indications Fabry's disease
  • Focus Adverse reactions
  • Sponsors Protalix Biotherapeutics
  • Most Recent Events

    • 27 Nov 2017 Results presented in a Protalix Biotherapeutics media release.
    • 27 Nov 2017 According to a Protalix Biotherapeutics media release, results from this trial were presented at the New Horizons in Fabry Disease Conference.
    • 20 Nov 2017 According to a Protalix BioTherapeutics media release, data will be presented at at the New Horizons in Fabry Disease Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top